Menu
  • The Novum Advantage
    • The Difference
    • Case Studies
  • Services
    • Comprehensive Services
    • Scientific Affairs
    • Phase I Early Clinical Development
    • Bioanalytical
    • Biosimilars
    • Phase II-IV Clinical Trial Management
    • Data Management
  • Company
    • Company Overview
    • Mission and Values
    • History
    • Leadership
    • Facility and Features
  • News
  • Careers
    • Careers Overview
    • Open Positions
  • Contact
    • General Inquiries
    • Business Development Inquiries
    • Request a Quote
    • Investigators
    • Employment Opportunities
  • Lambda
  • Participate in a study
  • The Novum Advantage
    • The Difference
    • Case Studies
  • Services
    • Comprehensive Services
    • Scientific Affairs
    • Phase I Early Clinical Development
    • Bioanalytical
    • Biosimilars
    • Phase II-IV Clinical Trial Management
    • Data Management
  • Company
    • Company Overview
    • Mission and Values
    • History
    • Leadership
    • Facility and Features
  • News
  • Careers
    • Careers Overview
    • Open Positions
  • Contact
    • General Inquiries
    • Business Development Inquiries
    • Request a Quote
    • Investigators
    • Employment Opportunities
  • Lambda
  • Participate in a study
News

EMA Updates the PRIME Pathway with Roadmaps

Posted on April 13, 2023 by Dipesh Chodvadia

EMA updates the PRIME pathway with roadmaps :

• To improve its PRIority MEdicines (PRIME) program, which aims to hasten the development of medicines for unmet needs, the European Medicines Agency (EMA) has taken recommendations from a recent report. The modifications include making sure that drug sponsors and regulators agree on the process and deadlines for getting the medicine through review.

• In order to give businesses creating medications for unmet medical needs more opportunity to interact with regulators, EMA introduced the pathway in 2016.

• The roadmap and tracker will take the role of the PRIME yearly update beginning in March 2023 as a pilot program for any items that have not previously been covered in a Kick-off meeting.

• The regulatory roadmap and development tracker, which contains details on anticipated regulatory filings and contacts with regulators, must be kept up to date and maintained by applicants as per EMA requirements.

• The revised guidance now permits submission preparedness meetings, which will be set up about a year before the applicant files their application for a marketing authorization.
Potential applicants would also be required to provide developed strategies for the generation of post-marketing proof, where appropriate.

• In order to arrange a submission readiness meeting with the PRIME Rapporteur and the assessment team, pertinent national experts, and the EMA product team, applicants are urged to get in touch with their PRIME scientific coordinator about 15 months prior to when they anticipate submitting their applications. The framework of the meeting will be the same as the kick-off meeting, but candidates will have an earlier opportunity to discuss what needs to be done before they submit their applications.

• The guidance indicates that in this situation, applicants “should consider that, to the extent feasible, the [submission] package should include all necessary data needed to support the intended [marketing application authorization (MAA)].” “This should take into account the possibility that applications for conditional marketing authorizations or marketing authorizations under unusual circumstances may not require as much evidence. At this time, applicants would also be required to demonstrate developed strategies for the creation of post-marketing evidence, as appropriate.

PRIME Eligibility requests Flowcharts:

PRIME: Areas Of Unmet Need

Outcome Of PRIME Eligibility Requests:

Outcome Of PRIME Eligibility Requests Per Therapeutic Area:

Orphan Outcome Through PRIME: Outcome Of PRIME Eligibility Requests For Orphan and Non-Orphan Medical Products:

Sources:
prime-analysis-first-5-years-experience_en.pdf (europa.eu)
European Medicines Agency guidance for applicants seeking access to PRIME scheme (europa.eu)

Share on:
linkedin-icon Created with Sketch.

Categories

  • Blogs
  • Clinical Research Insights
  • Events & Conferences
  • Industry News
  • Novum News
  • Uncategorized

Archives

Tags

  • Industry Updates
  • Ophthalmology
  • Clinical Trials
  • CPHI
  • Self Administration Studies
  • Dermatology

USA

Novum Pharmaceutical Research Services
3760 Pecos McLeod
Las Vegas, NV 89121 USA

Phone:

7024353902

SPAIN

Novum Therapeutics S.L.
World Trade Center, Moll de Barcelona, s/n, Edifici Est, 6º Planta
Barcelona, 08039 Spain

Email:

© 2025, Novum Pharmaceutical Research Services | Top CRO | USA | Canada | UK | Spain | India. All rights reserved.Privacy Policy

Site by Imagebox

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.

If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.

OkNo